Skin Cancer
FDA accepts Ameluz PDT sNDA for superficial basal cell carcinoma, with strong phase 3 clearance data and a September 2026 decision deadline.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Lung Cancer News Roundup: June 2026
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
New Research Links Food Access to Breast Cancer Biology
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5